In 120 patients with high-risk HR+/HER2− metastatic breast cancer, first-line palbociclib + ET improved median time-to-treatment failure vs mono-chemotherapy (17.2 vs 6.1 months; HR 0.46). OS did not differ; haematological toxicity was higher (96.8% vs 70.7%).
RCTn = 120
Schmidt et al. First-line ET plus palbociclib versus standard mono-chemotherapy in high-risk HR-positive/HER2-negative metastatic breast cancer and indication for chemotherapy: primary results from the randomized phase IV PADMA study